Patents Examined by Chang-Yu Wang
  • Methods for the treatment of mitochondrial diseases associated with a mutation in or gene resulting in a disruption of mitochondrial oxidative phosphorylation
    Patent number: 10793597
    Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: October 6, 2020
    Assignee: STEALTH BIOTHERAPEUTICS CORP
    Inventor: D. Travis Wilson
  • Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
    Patent number: 10774120
    Abstract: The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 15, 2020
    Assignee: The University of British Columbia
    Inventors: Neil R. Cashman, Steven S. Plotkin
  • Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
    Patent number: 10759837
    Abstract: The disclosure pertains to epitopes identified in A-beta including conformational epitopes, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: September 1, 2020
    Assignee: The University of British Columbia
    Inventors: Neil R. Cashman, Steven S. Plotkin
  • Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
    Patent number: 10751382
    Abstract: The disclosure pertains to methods of treating or preventing a disease or condition associated with and/or induced by soluble A-beta oligomer such as Alzheimer's disease by administering to a subject in need thereof conformation specific and/or selective antibodies or binding fragments thereof and related products.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: August 25, 2020
    Assignee: The University of British Columbia
    Inventor: Neil R. Cashman
  • PAC1 antibodies and uses thereof
    Patent number: 10738110
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 11, 2020
    Assignee: AMGEN INC.
    Inventors: Neeraj Jagdish Agrawal, Kevin Graham, Agnes Eva Hamburger, Christopher Mohr, Derek E. Piper, Kenneth William Walker, Zhulun Wang, Cen Xu
  • Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody
    Patent number: 10738109
    Abstract: Blood-brain barrier permeable peptide compositions that contain variable antigen binding domains from camelid and/or shark heavy-chain only single-domain antibodies are described. The variable antigen binding domains of the peptide compositions bind to therapeutic and diagnostic biomarkers in the central nervous system, such as the amyloid-beta peptide biomarker for Alzheimer's disease. The peptide compositions contain constant domains from human IgG, camelid IgG, and/or shark IgNAR. The peptide compositions include heavy-chain only single-domain antibodies and compositions with one or more variable antigen binding domain bound to one or more constant domains.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: August 11, 2020
    Assignee: ICB INTERNATIONAL, INC.
    Inventors: Ram S. Bhatt, Rishi S. Bhatt
  • Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody
    Patent number: 10723787
    Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: July 28, 2020
    Assignees: GENEURO SA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Hervé Perron, Julie Medina, Avindra Nath, Joseph Perry Steiner, Wenxue Li, Myound-Hwa Lee
  • Methods of reducing excitotoxicity-induced retinal ganglionic neuron degeneration by an orthodenticle HOMOLOG2 (OTX2) homeoprotein
    Patent number: 10722554
    Abstract: The invention relates to the use of a homeoprotein of the bicoid family, in particular of the Otx family, for enhancing the survival of cultivated retinal ganglion neurones, and for preventing or treating ganglion neuron degeneration particularly occurring in glaucoma.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: July 28, 2020
    Assignees: Centre National de la Recherche Scientifique, Ecole Normale Superieure
    Inventors: Alain Prochiantz, Kenneth Lee Moya
  • Methods for cardiomyocyte survival, proliferation or differentiation by NRG-2
    Patent number: 10717775
    Abstract: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: July 21, 2020
    Assignee: Acorda Therapeutics, Inc.
    Inventor: Mark Marchionni
  • Methods for treating a brain tissue damage by cultured adult pluripotent olfactory stem cells
    Patent number: 10696945
    Abstract: A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 30, 2020
    Assignee: China Medical University
    Inventors: Woei-Cherng Shyu, Chung-Y. Hsu, Der-Yang Cho, Chen-Huan Lin, Wei Lee, San-Yuan Chen, Long-Bin Jeng, Chang-Hai Tsai
  • P75NTR binding protein-Fc fusion protein and methods of treating pain
    Patent number: 10683339
    Abstract: The present invention relates to a new p75NTR neurotrophin binding protein (NBP)-Fc fusion protein comprising a p75NTR (NBP) portion and an immunoglobulin portion. In certain embodiments, the p75NTR (NBP)-Fc fusion protein is for use in the treatment of pain and/or a symptom of pain.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: June 16, 2020
    Assignee: Levicept Limited
    Inventor: Simon Westbrook
  • Methods for ameliorating memory impairment in a memory disorder caused by neuronal cell death or Abeta aggregation using a peptide
    Patent number: 10660935
    Abstract: A peptide consisting of an amino acid sequence of GPPGPAG (SEQ ID NO: 1) is disclosed. According to the present invention, a novel compound for improving memory disorder is provided.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 26, 2020
    Assignees: JAPAN BIO PRODUCTS Co., Ltd., National University Corporation University of Toyama
    Inventors: Chihiro Tohda, Taiichi Kaku, Hiroyuki Miyazaki
  • Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
    Patent number: 10653743
    Abstract: Compositions and methods for treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising compound PG-20N in a pharmaceutically acceptable carrier is described. According to another embodiment, the subject disclosure features method of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment. The method may comprise administering to the subject a therapeutically effective amount of a composition comprising PG-20N.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: May 19, 2020
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Victor J. Hruby, Minying Cai, Caurnel Morgan
  • Electrified compositions for determining the risk of developing adolescent idiopathic scoliosis through the use of GI protein receptor
    Patent number: 10620222
    Abstract: Methods for diagnosing a predisposition to developing a scoliosis (e.g., adolescent idiopathic scoliosis (AIS)) and identifying compounds for treating scoliosis based on the modulation of Gi protein-coupled receptor activity are described. Specific embodiments of the methods involve measuring a change in impedance signals of cells expressing a receptor coupled to a Gi protein with a ligand. To identify compounds useful in treatment, the cell is contacted with a test compound and a ligand. A higher impedance in the presence relative to the absence of said test compound is indicative that the test compound is useful for treating scoliosis.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: April 14, 2020
    Assignee: CHU Sainte-Justine
    Inventors: Alain Moreau, Marie-Yvonne Akoume Ndong
  • Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
    Patent number: 10538589
    Abstract: Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (CNS). The bifunctional fusion antibody provided herein comprise an antibody to an endogenous blood brain barrier (BBB) receptor and an enzyme deficient in mucopolysaccharidosis IIIB (MPS-IIIB). The fusion antibodies provided herein comprise alpha-N-acetylgulcosaminidase (NAGLU). The methods of treating an enzyme deficiency in the CNS comprise systemic administration of a fusion antibody provided herein.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: January 21, 2020
    Assignee: ARMAGEN INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Methods of reducing TDP-43-mediated neuronal cytotoxicity in amyotrophic lateral sclerosis by a UPF1 polypeptide or polynucleotide
    Patent number: 10533038
    Abstract: Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: January 14, 2020
    Assignee: Brandeis University
    Inventors: Greg Petsko, Dagmar Ringe, Shulin Ju
  • Methods for rescuing phenobarbital-resistance of seizures by ANA-12 or ANA-12 in combination with CLP290
    Patent number: 10525024
    Abstract: The present invention relates to the field of seizures. More specifically, the present invention provides compositions and methods for treating refractory seizures in neonates. In one embodiment, the method comprises the steps of (a) administering to the patient an amount of a KCC2 agonist and/or trkB antagonist effective to restore KCC2 expression to normal physiological levels; and (b) administering to the patient an effective amount of an anti-seizure medication.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: January 7, 2020
    Assignees: The Johns Hopkins University, Kennedy Krieger Institute, Inc.
    Inventor: Shilpa D. Kadam
  • Methods for the treatment of glaucoma and age-related macular degeneratiion by a peptide D-TRP-AIB
    Patent number: 10525097
    Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 7, 2020
    Assignee: Ramot at Tel Aviv University Ltd
    Inventor: Hermann Russ
  • Methods for treating back or neck pain caused by NGF using a therapeutic agent comprising REN-1820, ALE-0540 and capsaicin
    Patent number: 10517930
    Abstract: The invention provides a method for alleviating discogenic pain by administering a therapeutic agent that disrupts neuronal and/or vascular elements in the disc, which is typically a degenerated disc. Disruption of neuronal elements in the disk includes destroying nerve endings without substantially affecting the central body of the nerve, suppressing activation of the nerve endings, and inhibiting the growth of nerve endings into the disk. Disruption of vascular elements includes causing the vascular extensions to retract from the disk, or suppressing the formation of such extensions. The therapeutic agent may be administered locally via an interbody pump, a bolus or a depot, or may be administered systemically.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: December 31, 2019
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, Susan J. Drapeau, Jeffrey C. Marx
  • Antibodies to pyroglutamate amyloid-? and uses thereof
    Patent number: 10519223
    Abstract: The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A? and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other ?-amyloid-related diseases.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: December 31, 2019
    Assignee: Jannsen Pharmaceutica NV
    Inventors: Marc Mercken, Bianca Van Broeck, Marc Vandermeeren, Bart Hermans, Astrid Bottelbergs